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ABSTRACT
Objective: This study was aimed to determine the effects of coenzyme Q10 (CoQ10) administration on glucose homeostasis parameters, oxidative 
stress parameters, and biomarkers of inflammation among patients with Type 2 diabetes mellitus (T2DM).
Methods: A total of 28 T2DM patients (18 female [64.29%] and 10 male) of age range from 35 to 60 years old and mean±standard deviation age 
46.76±7.89 years. Participants were randomly allocated into two groups. Group A (n=14) received placebo and Group B (n=14) received 150 mg 
CoQ10 supplements for 12 weeks in addition to the already given oral hypoglycemic agent (glibenclamide) and dietary control. In addition, 25 age 
and sex-matched healthy volunteers were included in the study as a control group. Fasting blood samples were taken at the beginning of the study and 
after 6 and 12 weeks intervention to quantify glucose homeostasis parameters, oxidative stress, and biomarkers of inflammation.
Results: Compared with the placebo, CoQ10 supplementation resulted in a significant reduction in fasting blood glucose, glycosylated hemoglobin, 
improvement in antioxidant status, and reduction of inflammatory biomarkers.
Conclusion: Daily administration of 150 mg CoQ10 supplements for Type 2 diabetic patients for 12 weeks had beneficial effects on glycemic control, 
oxidative stress parameters, and inflammatory markers.
Keywords: Coenzyme Q10, Type 2 diabetes, Oxidative stress, Inflammation.
INTRODUCTION
The prevalence of Type 2 diabetes mellitus (T2DM) worldwide 
mandate continuous research to explore the mechanisms contributing 
to complications of the disease and at the same time fast and 
comprehensive scanning of old agents and investigation of new agents 
that acting by different mechanisms of action which may be beneficial 
to prevent or slow the appearance of diabetic complications [1]. 
Targeting of complications like oxidative stress and inflammation in 
T2DM represent interesting strategy that may delay the appearance 
of micro- and macro-vascular complication along with the main goal 
which is good glycemic control [2].
The patients with Type 2 diabetes are vulnerable to increased oxidative 
stress due to the excessive production of free radicals especially 
reactive oxygen species (ROS) and impaired antioxidant defense 
mechanism [3]. Poorly glycemic control leads to hyperglycemia which 
results in increased production of ROS which causes membrane damage 
due to the peroxidation of membrane lipids and protein glycation [4]; 
for this reason, the targeting of oxidative stress is necessary in diabetic 
patients. Many studies have shown that the use of antioxidants, as 
well as herbal agents, might help control the oxidative stress [5]. Many 
studies suggest a central role for oxidative stress in the pathogenesis of 
this multifaceted metabolic disorder. This has prompted investigations 
in the use of antioxidants as a complementary therapeutic approach [6].
Many studies reporting the relation between inflammation and T2DM 
have showed the role of inflammation in the development of insulin 
resistance and other pathogenic processes of T2DM [7]. It has been 
shown that the proinflammatory cytokine tumor necrosis factor-α 
(TNF-α) was able to induce insulin resistance [8]. It has been suggested 
that abnormal levels of chemokines released by adipose tissue activate 
monocytes and increase the secretion of pro-inflammatory adipokines. 
Such cytokines, in turn, enhance insulin resistance in adipose and other 
tissues, thereby increasing the risk for T2DM [9].
Exposure to exogenous factors triggers the release of pro-inflammatory 
cytokines like TNF-α and other interleukins, these cytokines are derived 
primarily from macrophages and can directly enhance insulin resistance 
in adipocytes, muscle and liver cells [10]. Cytokines also act on the liver 
to increase the production of very-low density lipoproteins (LDLs), 
leading to diabetic dyslipidemia [11], furthermore, cytokines deactivate 
the liver X receptors, resulting in an increased rate of cholesterol 
accumulation [12], and ultimately trigger the hepatic production and 
secretion of acute-phase proteins such as C-reactive protein (CRP); 
The synthesis of acute-phase reactants following the cytokine release 
characterizes the early stages of T2DM and exhibits graded increases as 
the disease progresses and clinical complications ensue [13,14].
Coenzyme Q10 (CoQ10)
CoQ10 was first isolated in 1957 from beef mitochondria and is known 
to be highly concentrated in heart-muscle cells due to the high energy 
requirements of this cell type. It is a naturally occurring fat-soluble 
vitamin-like quinone. It is also called ubiquinone as it is ubiquitous or 
present in all eukaryotic cells [15]. CoQ10, also known as ubiquinone, 
and abbreviated at times to (CoQ10, Q10, where Q refers to the 
quinone chemical group, and 10 refers to the number of isoprenyl 
chemical subunits in its tail). This oil-soluble, vitamin-like substance 
is present in most eukaryotic cells, primarily in the mitochondria. 
It is a component of the electron transport chain and participates 
in aerobic cellular respiration, generating energy in the form of 
adenosine triphosphate [16]. CoQ10, or ubiquinone, is an endogenously 
synthesized lipid. Intracellular synthesis, which depends on the 
mevalonate pathway, is the major source of CoQ10. The mevalonate 
pathway is a sequence of cellular reactions leading to farnesyl 
pyrophosphate, the common substrate for the synthesis of cholesterol, 
and CoQ10. Cells synthesize CoQ10 de novo [17]. The well recognized 
biochemical functions of CoQ are mitochondrial energy coupling and 
its action as a primary regenerating antioxidant. Less well-established 
functions include oxidant action in the generation of signals and control 
of cellular redox state. By participation in transmembrane electron 
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transport, CoQ can carry reducing equivalents to the inside of vesicles 
or to the outside of cells. In addition, there is evidence that CoQ can take 
part in control of membrane structure and phospholipid status [18]. 
Serum CoQ10 levels in Type 2 diabetic patients are often decreased and 
may be associated with subclinical diabetic cardiomyopathy, reversible 
by CoQ10 supplementation [19].
The aim of this randomized, placebo-controlled clinical trial was 
to study the antioxidant and anti-inflammatory effect of CoQ10 
supplementation in Iraqi patients with Type 2 diabetes.
METHODS
This is a prospective, placebo-controlled clinical trial carried out 
on patients with T2DM who attend the Specialized Center for 
Endocrinology and Diabetes-AL-Risafa, Directorate of Health-Baghdad. 
After getting Institutional Scientific and Ethical Committee approval, 
28 patients with Type 2 diabetes mellitus were participated in this 
study, 18 female (64.29%) and 10 male (35.71%) of age range from 35 to 
60 years old and mean±standard deviation (SD) age 46.76±7.89 years. 
25 age and sex-matched healthy volunteers were included in the study 
as a control group, 17 female (68%) and 8 male (32%) of mean±SD 
age 46.40±7.71 years, respectively; an informed consent from each 
participant was done.
The inclusion criteria: Patients with Type 2 diabetes mellitus on a 
sulfonylurea (glibenclamide), and have disease duration of 5-10 years. 
The exclusion criteria: They should not have other associated 
chronic diseases like liver and kidney disorders and cardiovascular 
complications. The patients who are pregnant and breastfeeding are 
excluded. They should not be on insulin therapy or other antidiabetic 
drugs, or on antioxidant drugs, and any associated drugs should be 
considered. They should not take other hypolipidemic agent; anti-
inflammatory or nonsteroidal anti-inflammatory drugs. Diabetic 
patients were assigned as follow:
1. Group A includes 14 patients treated with placebo in capsule dosage 
form in addition to the already given oral hypoglycemic agent 
(glibenclamide) and dietary control, for 12 weeks
2. Group B includes 14 patients treated with CoQ10 75 mg soft gelatin 
capsule twice daily (150 mg/day) in addition to the already given 
oral hypoglycemic agent (glibenclamide) and dietary control, for 
12 weeks.
Sample collection and preparation
After 12 hrs fasting, blood samples were collected from all subjects 
by venepunture (10 ml), before starting drug treatment (as baseline 
samples) and then after 6 weeks and 12 weeks of treatment to follow 
the changes in the studied parameters.
Blood samples were divided into two tubes, one heparinized tube (1 ml 
of whole blood used for glycated hemoglobin [HbA1c] determination) 
and another part was collected in plane tube, then centrifuged at 
3000 rpm for 10 minutes at 4°C. After centrifugation and isolation of 
cellular fraction, the obtained plasma fraction was divided into three 
parts in ependorff tubes and stored frozen until analysis performed.
Biochemical assay methods
Measurement of serum glucose level (fasting plasma glucose)
Serum glucose level was evaluated using a readymade kit for this 
purpose, according to the method [20], which is based on enzymatic 
oxidation of glucose to form glucuronic acid and hydrogen peroxide, and 
the reaction of the later with phenol and formation of quinonimine was 
followed spectrophotomertically at 505 nm. Results were expressed as 
mmol glucose/L, based on comparison with a standard glucose solution 
treated with the same method.
Determination of HbA1c
The variant HbA1c program utilizes the principles of ion exchange 
high-performance liquid chromatography for the automatic and 
accurate separation of HbA1c. Prepared samples are automatically 
injected into the analytical flow path and applied to the cation exchange 
column, where the hemoglobin is separated, based on the attraction of 
hemoglobin to the column material. The separated hemoglobin then 
passes through the flow cell of the filter photometer, where changes 
in the absorbance at 415 nm are measured. Samples are required to 
hemolyze the blood and remove schiff base. Samples are the first diluted 
with hemolysis reagent and then incubated at 18-28°C for a minimum 
of 15 minutes [21].
Measurement of serum malondialdehyde (S. MDA)
MDA is a by-product of lipid peroxidation and its measurement is 
based on the reaction of thiobarbituric acid (TBA) with MDA forming 
TBA-2MDA adducts. According to the standard method [22], which 
is modified by Gilbert et al. [23]. The method included the addition 
of 1.75 ml of saline azide to 0.25 ml plasma. Then, the mixture was 
centrifuged and 2 ml of supernatant was mixed with 0.5 ml of H2O 
and 0.5 ml of 1% TBA in 0.05 M NaOH. The mixture was incubated in 
a boiling water bath for 15 minutes to achieve color development. The 
tubes were cooled under tap water, and the extent of MDA production 
was estimated from the absorbance at 532 nm. MDA concentration was 
calculated using a molar absortivity coefficient of 1.56 × 105 M−1 cm−1, 
and the results were expressed as µmol MDA/L.
Measurement of serum glutathione (S. GSH) levels
GSH contents (measured as total sulfhydryl groups) were measured 
according to the method [24]. 0.5 ml of serum was mixed with 206 ml 
of 3 mM dithionitrobenzene prepared in 0.1 M phosphate buffer 
(pH 8). The yellowish color chromophor formed was measured 
spectrophotometrically at 412 nm during 2 minutes and the 
concentration of GSH was calculated using a standard curve utilized for 
this purpose.
Measurement of serum superoxide dismutase (S. SOD) levels
SOD is one of the most important antioxidative enzymes. It catalyzes 
the dismutation of the superoxide anion into hydrogen peroxide 
and molecular oxygen. The sensitive SOD assay kit utilizes WST-1 
that produces a water-soluble formazan dye on reduction with 
superoxide anion. The rate of the reduction with a superoxide anion 
is linearly related to the xanthine oxidase activity, and is inhibited by 
SOD. Therefore, the inhibition activity of SOD can be determined by a 
colorimetric method. Detection method-absorbance (450 nm) [25].
Measurement of serum oxidized LDL (S. Ox-LDL)
Measurement of Ox-LDL level in human serum done using an enzyme 
immunoassay (ELISA) kit for the quantitative determination of human 
autoantibodies (immunoglobulin G and immunoglobulin M) against 
Ox-LDL in human serum [26].
Measurement of serum TNF-α (S. TNF-α) level
TNF-α human ELISA is a sandwich assay for the determination of TNF-α 
in serum. During the first incubation period, TNF-α in patient serum 
samples is captured by the monoclonal antibody to human TNF-α coated 
on the wall of the microtiter wells. After washing away the unbound 
components from samples, a peroxidase-labeled second monoclonal 
antibody conjugate is added to each well and then incubated. After 
a second washing step, the bound enzymatic activity is detected by 
addition of tetramethylbenzidine (TMB) chromogen-substrate. Finally, 
the reaction is terminated with an acidic stop solution. The intensity of 
reaction color is directly proportional to the concentration of human 
TNF-α in the sample [27].
CRP
Microtiterstrips coated with anti-CRP are incubated with diluted 
standard sera and patient samples. During this incubation step, CRP 
is bound specifically to the wells. After removal of the unbound serum 
proteins by a washing procedure, the antigen-antibody complex in 
3
Innovare Journal of Medical Science, Vol 4, Issue 5, 1-6
 Sahib 
each well is detected with specific peroxidase-conjugated antibodies. 
After removal of the unbound conjugate, the strips are incubated with 
a chromogen solution containing TMB and hydrogen peroxide; a blue 
color develops in proportion to the amount of immune complex bound 
to the wells of the strips. The enzymatic reaction is stopped by the 
addition of 1 N acidic solution, and the absorbance values at 450 nm 
are determined [28].
Statistical analysis
The results were expressed as mean±SD. Student’s t-test for paired 
and unpaired sample and ANOVA test was used to examine the degree 
of significance, p<0.05 considered significant and <0.001 considered 
highly significant.
RESULTS
Comparison between healthy volunteers (control) and patients 
with diabetes in relation to laboratory parameters
Statistical comparison is done between healthy subjects (control group) 
and patients group at baseline (before treatment) for the studied 
parameters including fasting blood sugar (FBS), (bA1c, S. GSH, S. MDA, 
S. SOD, S. ox-LDL, S. TNF-α, and serum CRP (S. CRP).
Analysis of t-test revealed high statistically significant changes 
(p<0.001) in the level of FBS, S. HbA1c, S. GSH, S. MDA, S. SOD, S. ox-
LDL, S. TNF-α, and S. CRP in patients with diabetes in comparison with 
healthy group, Table 1.
Effect of CoQ10 on glycemic control in patients with Type 2 
diabetes in comparison with baseline and placebo-treated group
This study demonstrated that in comparison with value at baseline in 
the same group, the level of FBS significantly decreased after 6 weeks 
in placebo and CoQ10 treated group. After 12 weeks, no significant 
difference in FBS level of placebo group, while a high significant 
decrease in FBS level of CoQ10 treated group was recorded. In 
comparison with a placebo-treated group at corresponding duration, 
after 6 weeks there is no significant difference in FBS in CoQ10 group. 
While after 12 weeks, there was a significant decrease in FBS level of 
CoQ10 group. Concerning glycosylated hemoglobin, Table 2 showed 
that in comparison with value at baseline in the same group after 
6 weeks there was a significant decrease in HbA1c in placebo and 
CoQ10 groups. After 12 weeks, no significant difference in HbA1c 
in placebo group, and a high significant decrease in HbA1c in CoQ10 
group. In comparison with a placebo-treated group at corresponding 
duration, after 6 weeks there is no significant difference in HbA1c in 
CoQ10 group. After 12 weeks, a significant decrease in HbA1c of CoQ10 
group was seen (Table 2).
Effect of CoQ10 on oxidative stress parameters in patients with 
Type 2 diabetes in comparison with baseline and placebo-treated 
patients
CoQ-10 supplementation to Type 2 diabetic patients resulted in high 
significant increase in S. GSH compared with value at baseline in the 
same group after 6 weeks; there is a significant increase in S. GSH in the 
placebo group.
After 12 weeks, no significant difference in S. GSH in the placebo group 
and highly significant increase in S. GSH in CoQ10 group.
In comparison with a placebo-treated group at corresponding duration, 
after 6 weeks there is no significant difference in S. GSH level of CoQ10 
group. After 12 weeks, there is high significant increase in S. GSH level 
in CoQ10 group.
In relation to S. MDA, in comparison with value at baseline in the same 
group after 6 weeks, there is no significant difference in S. MDA in 
placebo group and high significant decrease in S. MDA in CoQ10, group. 
After 12 weeks, no significant difference in S. MDA in placebo group and 
a high significant decrease in S. MDA in CoQ10 group. In comparison 
with a placebo-treated group at corresponding duration, after 6 weeks 
there is no significant difference in S. MDA in CoQ10 group, after 
12 weeks, there is a high significant decrease in S. MDA in CoQ10.
Concerning S. SOD, in comparison with value at baseline in the same 
group after 6 weeks, there is no significant difference in S. SOD in 
placebo and CoQ10 groups, after 12 weeks, no significant difference in 
S. SOD in CoQ10 group, and significant increase in S. SOD in placebo 
group. In comparison with a placebo-treated group at corresponding 
duration, after 6 and 12 weeks, there is no significant difference in 
S, SOD in CoQ10 group. In relation to S. ox-LDL, in comparison with 
value at baseline in the same group after 6 and 12 weeks there is no 
significant difference in S. ox-LDL in placebo, and high significant 
decrease in S. ox-LDL in CoQ10 group. In comparison with a placebo-
treated group at corresponding duration, after 6 weeks no significant 
difference in S. ox-LDL in CoQ10 group, after 12 weeks, high significant 
decrease in S. ox-LDL in CoQ10 group, (Table 3).
Effect of CoQ10 on inflammatory markers in patients with Type 2 
diabetes in comparison with baseline and placebo-treated patients
This study demonstrated that in comparison with value at baseline 
in the same group after 6 weeks there is no significant difference in 
S. TNF-α in placebo group, while there is high significant difference 
in S. TNF-α level of CoQ10 group. After 12 weeks, there is a significant 
increase in S. TNF-α in placebo group, and high significant decrease in 
Table 2: Comparison of FBS and HBA1c at different duration in each group
Group FBS (mmol/l) HbA1c (%)
Baseline 6 weeks 12 weeks Baseline 6 weeks 12 weeks
Placebo (n=14) 11.68+3.64 10.62+2.94* 11.62+2.79 8.35+1.93 8.6+1.94 8.15+1.61
CoQ10 (n=14) 11.2+3.66 9.39+3.92* 8.56+2.95**a 7.81+1.49 7.11+2.25* 6.42+2.23**a
FBS: Fasting blood sugar, HbA1c: Glycosylated hemoglobin. Comparison is with baseline value *Significant difference from baseline (p<0.05), **Highly significant 
difference from baseline (p<0.001). aSignificant difference (p<0.05) between drug group and placebo group at corresponding duration. bHighly significant 
difference (p<0.001) between drug group and placebo group at corresponding duration
Table 1: Baseline comparison of control group with Type 2 
diabetic patients
Parameters Control (n=25) Patients (n=28)
FBS (mmol/l) 4.06+0.27 11.26+3.58**
HbA1c (%) 4.66+0.54 8.18+142**
S. GSH (µmol/l) 0.98+0.08 0.54+0.12**
S. MDA (µmol/l) 0.85+0.09 1.82+0.35**
S. SOD (µmol/l) 74.42+4.47 28.81+7.61**
S. ox-LDL (U/ml) 23.84+1.86 47.83+7.15**
S. TNF-α (pg/ml) 31.88+5.8 65.64+8.35**
S. CRP (µg/ml) 1.15+0.26 5.18+1.95**
FBS: Fasting blood sugar, HbA1c: Glycosylated hemoglobin, S. GSH: Serum 
glutathione, S. MDA: Serum malondialdehyde, S. SOD: Serum superoxide 
dismutase, S. ox-LDL: Serum oxidized low density lipoprotein; S. TNF-α: Serum 
tissue necrosis factor alpha, S. CRP: Serum C-reactive protein. Results 
represent mean±SD; **Highly significant difference (p<0.001) from control 
group
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S. TNF-α level of CoQ10 group. In comparison with a placebo-treated 
group at corresponding duration, after 6 weeks no significant difference 
in S. TNF-α in CoQ10 group, while after 12 weeks, significant decrease 
in S. TNF-α was seen in CoQ10 group.
In relation to S. CRP, in comparison with value at baseline in the same 
group after 6 and 12 weeks there is no significant difference in S. CRP in 
placebo group and high significant decrease in S. CRP in CoQ10, group.
In comparison with a placebo-treated group at corresponding duration, 
after 6 and 12 weeks, there is high significant decrease in S. CRP in 
CoQ10 group, (Table 4).
DISCUSSION
The data obtained in this study demonstrates the antioxidant and 
anti-inflammatory effects of CoQ10 supplementation 150 mg daily 
in combination with an oral hypoglycemic agent (glibenclamide) 
for Type 2 diabetic patients, the used dose was well tolerated by 
the patients and there was no any adverse effect appears during the 
treatment course.
In other clinical trials, a total of 194 Type 2 diabetic patients received 
200 mg CoQ10 or a placebo daily for 12 weeks, resulted in good 
glycemic control [29]. CoQ10 supplementation in this population 
raised plasma CoQ10 levels, improved endothelial function in the 
brachial artery, significantly decreased both systolic and diastolic 
blood pressure, and decreased HbA1c. It has been demonstrated that 
12 weeks supplementation with CoQ10 improves clinical outcomes and 
nerve conduction parameters of diabetic polyneuropathy; furthermore, 
it reduces oxidative stress without significant adverse events [30].
Results obtained by Mezawa et al. studied the effect of supplementation 
of the reduced form of CoQ10, ubiquinol, in addition to conventional 
glucose-lowering agents in nine subjects (3 males and 6 females) with 
Type 2 diabetes; the subjects were assigned to receive an oral dose 
of 200 mg ubiquinol daily for 12 weeks. The results obtained showed 
improvement in glycemic control by improving insulin secretion 
without any adverse effects [31].
Kolahdouz Mohammadi et al. reported in a randomized double-blind 
placebo-controlled trial, 64 Type 2 diabetic patients were randomly 
assigned to receive either 200 mg Q10 or placebo daily for 12 weeks, 
the results were improved glycemic control, total and LDL cholesterol 
while triglycerides and high-density lipoprotein cholesterol levels were 
no significantly improved [32].
Another study done by Zahedi et al. showed that supplementation 
of 150 mg CoQ10 or placebo daily for 12 weeks to 50 patients with 
diabetes who randomly allocated into two groups to receive either 
treatment resulted in significant lowering of fasting blood glucose level 
and HbA1c levels in CoQ10 treated group compared to placebo with 
which results obtained in this study are compatible [33].
The effect of supplementation of 150 mg CoQ10 to diabetic patients 
significantly improve the oxidative stress parameters after 12 weeks 
in this study, this finding can be seen in other studies, Shen and 
Pierce 2015, reported that the pathogenesis of Type 2 diabetes mellitus 
may be partly contributed to mitochondrial dysfunction secondary 
to oxidative stress, beside deficiency in CoQ10 which is often present 
among patients with Type 2 diabetes made CoQ10 a potent antioxidant 
to scavenge excessive ROS and provide protection to cells, especially 
mitochondria from oxidative damage. Leading to restoration of CoQ10 
level among patients with T2DM and alleviate oxidative stress, preserve 
mitochondrial function, and eventually lead to improvement of glycemic 
control [34].
The previous study by El-ghoroury et al. revealed that plasma and 
platelet MDA level, as a marker of oxidative stress, were significantly 
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CoQ10, as antioxidant capacity, was significantly lower in diabetic 
patients than in controls. They showed that there was a negative 
correlation between plasma CoQ10 concentrations and glycosylated 
hemoglobin. They concluded that Type 2 diabetic patients are at 
increased risk of oxidative stress manifested by increased plasma MDA 
level as well as platelet MDA and decreased CoQ10 plasma level [35].
Montano et al. demonstrated that 12 weeks CoQ10 treatment 
significantly improved the extracellular redox balance in diabetic 
patients; they suggest that prolonged treatment may have beneficial 
effects also on clinical outcome in diabetes [36].
Raygan et al. showed that CoQ10 supplementation resulted in a 
significant reduction in serum insulin levels. In addition, the patients 
who received CoQ10 supplements had a significant increase in plasma 
total antioxidant capacity concentrations compared with the placebo 
group. In addition, compared with the placebo group, a significant 
positive change in plasma glutathione and a significant reduction in 
MDA were seen among patients who received CoQ10 supplement [37].
Akbari Fakhrabadi et al. study the effect of CoQ10 (200 mg/d) or 
placebo for 12 weeks on oxidative stress parameters, glycemic control 
and inflammation in 70 diabetic patients recruited for a double-
blind randomized clinical trial, the mean insulin sensitivity and total 
antioxidant capacity concentration significantly increased in the 
CoQ10 group compared to the placebo after the trial. CRP significantly 
decreased in the intervention group compared to placebo after the 
trial [38]. The above-mentioned studies clearly support the findings 
obtained in this study, and conclusion can be made depending on 
obtained results that administration of CoQ10 (150 mg/day) as adjuvant 
therapy improve glycemic control, oxidative stress parameters, and 
inflammatory markers in Iraqi diabetic patients.
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